- Home
- MHUA vs KZIA Comparison
MHUA vs KZIA Comparison
Compare MHUA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- KZIA
- Stock Information
- Founded
- MHUA 1990
- KZIA 1994
- Country
- MHUA China
- KZIA Australia
- Employees
- MHUA N/A
- KZIA N/A
- Industry
- MHUA Medical Specialities
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- KZIA Health Care
- Exchange
- MHUA Nasdaq
- KZIA Nasdaq
- Market Cap
- MHUA 12.8M
- KZIA 12.6M
- IPO Year
- MHUA 2022
- KZIA 1999
- Fundamental
- Price
- MHUA $0.50
- KZIA $5.41
- Analyst Decision
- MHUA
- KZIA Strong Buy
- Analyst Count
- MHUA 0
- KZIA 1
- Target Price
- MHUA N/A
- KZIA $20.00
- AVG Volume (30 Days)
- MHUA 1.0M
- KZIA 148.4K
- Earning Date
- MHUA 11-22-2024
- KZIA 11-19-2024
- Dividend Yield
- MHUA N/A
- KZIA N/A
- EPS Growth
- MHUA 29.93
- KZIA N/A
- EPS
- MHUA 0.37
- KZIA N/A
- Revenue
- MHUA $94,252,537.00
- KZIA $382.00
- Revenue This Year
- MHUA N/A
- KZIA $4,053,954.00
- Revenue Next Year
- MHUA N/A
- KZIA N/A
- P/E Ratio
- MHUA $1.41
- KZIA N/A
- Revenue Growth
- MHUA N/A
- KZIA N/A
- 52 Week Low
- MHUA $0.45
- KZIA $1.90
- 52 Week High
- MHUA $2.81
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- MHUA 32.99
- KZIA 50.25
- Support Level
- MHUA $0.45
- KZIA $5.21
- Resistance Level
- MHUA $0.53
- KZIA $6.88
- Average True Range (ATR)
- MHUA 0.06
- KZIA 0.76
- MACD
- MHUA -0.01
- KZIA -0.11
- Stochastic Oscillator
- MHUA 12.99
- KZIA 22.80
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.